Capital Fund Management (CFM)’s Ligand Pharmaceuticals LGND Stock Holding History

Capital Fund Management (CFM)’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-3,334	Closed	-$209K	–	1784
2019 Q2	$237K	Buy	+3,334	New	+$246K	﹤0.01%	1469
2018 Q3	–	Sell	-4,716	Closed	-$711K	–	2120
2018 Q2	$609K	Buy	4,716 +1,895	+67%	+$211K	﹤0.01%	1525
2018 Q1	$291K	Buy	+2,821	New	+$279K	﹤0.01%	1646
2017 Q2	–	Sell	-10,104	Closed	-$667K	–	1606
2017 Q1	$667K	Sell	10,104 -15,780	-61%	-$1.04M	0.01%	1057
2016 Q4	$1.64M	Sell	25,884 -243	-0.9%	-$15.3K	0.01%	841
2016 Q3	$1.66M	Buy	26,127 +18,678	+251%	+$1.37M	0.02%	818
2016 Q2	$554K	Buy	+7,449	New	+$553K	0.01%	1143
2015 Q3	–	Sell	-5,290	Closed	-$333K	–	1555
2015 Q2	$333K	Buy	+5,290	New	+$289K	﹤0.01%	1223
2014 Q4	–	Sell	-38,151	Closed	-$1.12M	–	1709
2014 Q3	$1.12M	Buy	+38,151	New	+$1.27M	0.01%	887

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Capital Fund Management (CFM)'s LGND Position: Q3 2019 in Review

Capital Fund Management (CFM) sold out of Ligand Pharmaceuticals (LGND) in Q3 2019, closing a stake of 3,334 shares — an estimated $209K sold.

Capital Fund Management (CFM) first reported a position in LGND in Q3 2014 and held it in 9 quarters. The position peaked at $1.66M in Q3 2016. 275 funds tracked by Wall St. Rank hold LGND as of Q3 2019.

Capital Fund Management (CFM) reported no remaining Ligand Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Capital Fund Management (CFM) sold 3,334 Ligand Pharmaceuticals shares in Q3 2019, an estimated $209K.
Capital Fund Management (CFM) first reported a position in Ligand Pharmaceuticals in Q3 2014 and held it in 9 quarters.
Capital Fund Management (CFM)'s Ligand Pharmaceuticals position peaked at $1.66M in Q3 2016.
275 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2019.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2019, filed 13 Nov 2019.